Hereditary cancers account for 5%-10% of all cancers, resulting in a considerable population burden of morbidity and mortality. Individuals with an inherited susceptibility to cancer require special and long-term care, and clinical management necessitates interdisciplinary cooperation among multiple providers, including genetic counselors, oncologists, primary care physicians, and surgeons. One of the most challenging tasks facing these individuals is understanding their risk of disease and applying this understanding to decisions involving risk management and disclosure of genetic information to family members.
The Cancer Moonshot℠ Blue Ribbon Panel Report, published in October 2016, identified clinical and research opportunities to expand use of proven cancer prevention and early detection strategies to reduce cancer risk and cancer health disparities. The objective of the communication and decision-making for individuals with an inherited susceptibility to cancer initiative was to improve the current state of early detection, genetic counseling, and genetic testing by supporting research to develop, test, and evaluate interventions and implementation approaches to improve cancer risk communication between individuals with an inherited susceptibility to cancer (and their families) and providers so that affected individuals could make informed clinical risk management decisions. Projects were encouraged to include a variety of clinical care settings, genetic counseling and testing methods, and ethnically, socioeconomically, and geographically diverse populations.
Current grants were funded in response to the following NOFOs:
-
RFA-CA-19-001, U01, Clinical Trial Optional (expired January 10, 2019)
-
RFA-CA-20-006, U01, Clinical Trial Optional (expired January 22, 2020)
Active Grants
|
PI Name |
Organization Name |
Project Title |
Project Number |
|---|---|---|---|
|
Angela R. Bradbury, M.D. |
University of Pennsylvania |
A Randomized Hybrid Type I Effectiveness-Implementation Study of an Ehealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer Predisposition (EREACH) |
|
|
Daniel C. Chung, M.D. |
Massachusetts General Hospital |
Development and Implementation of Electronic Decision AIDS for Genetic Testing in Inherited Cancer Syndromes |
|
|
Jada G. Hamilton, Ph.D., M.P.H. |
Sloan-Kettering Inst Can Research |
Prospective Trial of a Linguistically and Culturally Appropriate Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Diverse Cancer Patients |
|
|
Steven J. Katz, M.D., M.P.H. |
University of Michigan At Ann Arbor |
A Population-Based Virtual Solution to Reduce Gaps in Genetic Risk Evaluation and Management in Families at High Risk for Hereditary Cancer Syndromes: the Georgia-California Genelink Trial |
|
|
Jennifer W. Mack, M.D., M.P.H. |
Dana-Farber Cancer Inst |
The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes |
|
|
Tuya Pal, M.D. |
Vanderbilt University Medical Center |
Improving Care After Inherited Cancer Testing (IMPACT) Study |
Funding Opportunities
Although there are currently no Cancer Moonshot notices of funding opportunities (NOFOs) accepting applications specifically related to communication and decision-making for individuals with an inherited susceptibility to cancer, investigators with related research ideas may consider submitting applications to:
|
Title |
Announcement # |
Expiration Date |
Contact |
|---|---|---|---|
|
Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)
|
PAR-13-309 (R21 Clinical Trial Optional)
|
September 08, 2022 |
|
|
NOSI: Development and Preliminary Testing of Health-related Behavioral Interventions |
NOT-OD-20-106 (Notice of Special Interest)
|
September 26, 2022 |
|
|
NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2020 (R03) |
PAR-20-052 (NCI Omnibus R03 Clinical Trial Optional) |
January 08, 2023 |
|
|
NIH Research Project Grant (R01) |
PA-20-185 (Parent R01 Clinical Trial Not Allowed) |
May 08, 2023 |
|
|
Cancer Prevention and Control Clinical Trials Grant Program (R01) |
PAR-21-035 (R01 Clinical Trial Required)
|
January 08, 2024 |
|
|
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) |
PAR-21-190 (R01 Clinical Trial Optional)
|
March 08, 2024 |
|
Areas of Continued Interest/Emphasis for New Applications
- Communication strategies for return of an uninformative test result or variant of uncertain significance (VUS)
- Behavioral and psychological outcomes of receiving an uninformative test result or VUS result
- Technological, verbal, and written communication approaches to genetic counseling and testing that promote understanding of genetic risk and help guide clinical management decisions
- Decision-making tools and approaches to promote understanding of disease risk and help guide clinical management decisions
- Delivery of culturally competent genetic counseling that addresses the needs of medically underserved individuals
Contact
